首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1518459

重組蛋白市場規模 - 按產品和服務、應用、宿主細胞、最終用途和全球預測，2024 年 - 2032 年

Recombinant Proteins Market Size - By Products & Services, Application, Host-cell, End-use & Global Forecast, 2024 - 2032

出版日期: 2024年04月19日 | 出版商:

Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在慢性病盛行率上升的推動下，重組蛋白市場收入在 2024 年至 2032 年期間將以超過 7.1% 的複合年成長率成長。 Physiopedia 報告稱，全世界大約三分之一的成年人受到多種慢性病的影響。重組蛋白在開發生物製藥和治療這些複雜病症的標靶療法中發揮著至關重要的作用。它們模仿天然蛋白質和選擇性標靶疾病機制的能力使它們在創新療法的開發中不可或缺。

此外，基因工程和蛋白質表現技術的進步使得能夠更有效和精確地操縱遺傳物質來產生所需的蛋白質。專注於加速新治療和診斷產品的開發將提振未來幾年的市場前景。

重組蛋白產業根據產品和服務、宿主細胞、最終用途和地區進行分類。

到 2032 年，酵母和真菌宿主細胞轉譯後修飾將快速成長。基於酵母的系統，包括釀酒酵母和畢赤酵母，由於其穩健性和與複雜蛋白質結構的兼容性而被廣泛用於工業規模生產。黑麴菌和里氏木黴等真菌也越來越受到關注，特別是在酵素生產和工業生物技術應用領域。

到 2032 年，診斷領域將穩定成長，因為重組蛋白在檢測疾病和監測患者健康的診斷分析中至關重要。它們用於生產對酶聯免疫吸附測定 (ELISA)、側流測定和分子診斷等診斷測試至關重要的抗原、抗體和酶。重組蛋白的特異性、敏感性和重現性使其成為開發準確可靠的診斷工具的理想選擇。隨著全球醫療保健產業強調早期疾病檢測和個人化醫療，診斷中對重組蛋白的需求預計將會成長。

歐洲重組蛋白產業將在 2024 年和 2032 年出現良好的成長趨勢，其特點是強大的生物製藥產業、廣泛的研究基礎設施和支持性的監管框架。德國、瑞士和英國等國家是生物技術和藥物研究的領先中心，推動了藥物發現和開發中對重組蛋白的需求。此外，生物製藥產品嚴格的品質標準和優惠的報銷政策有助於市場擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 對生物製藥和治療性蛋白質的需求不斷增加
  - 蛋白質工程的進展
  - 慢性病和傳染病的盛行率不斷上升
- 產業陷阱與挑戰
  - 生產成本高
  - 嚴格的監管要求
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

主要趨勢
產品
- 細胞激素和生長因子
  - 干擾素 (IFN)
  - 白血球介素 (IL)
  - 其他細胞激素和生長因子
- 抗體
- 免疫檢查點蛋白
- 病毒抗原
- 酵素
  - 激酶
  - 代謝酵素
  - 其他酵素
- 重組調節蛋白
- 荷爾蒙
- 其他產品
生產服務

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
藥物發現與開發
- 生物製劑
- 疫苗
- 細胞和基因療法
研究
診斷
其他應用

第 7 章：市場估計與預測：按宿主細胞，2021 - 2032

主要趨勢
哺乳動物系統
昆蟲細胞
酵母和真菌
細菌細胞
其他宿主細胞

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
製藥和生物技術公司
學術及研究機構
合約研究組織 (CRO)
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abcam Limited
Abnova Corporation
Bio-Rad Laboratories, Inc.
Enzo Life Sciences, Inc.
GenScript Biotech Corporation
Merck KGaA
Proteintech Group, Inc.
RayBiotech, Inc.
R&D Systems, Inc.
Sino Biological, Inc.
STEMCELL Technologies Inc.
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 9114

The Recombinant Proteins Market revenue will grow at over 7.1% CAGR during 2024-2032, driven by the rising prevalence of chronic diseases. Physiopedia reports that approximately one-third of adults worldwide are impacted by multiple chronic conditions. Recombinant proteins play a crucial role in developing biopharmaceuticals and targeted therapies for treating these complex conditions. Their ability to mimic natural proteins and selectively target disease mechanisms makes them indispensable in the development of innovative treatments.

Moreover, advancements in genetic engineering and protein expression technologies enable more efficient and precise manipulation of genetic material to produce desired proteins. The focus on accelerating the development of new therapeutic and diagnostic products will bolster the market outlook in the coming years.

The recombinant proteins industry is classified based on products & services, host cell, end-use, and region.

The yeast & fungi host-cell segment will grow rapidly through 2032. These microorganisms offer advantages such as rapid growth rates, high protein expression yields, and post-translational modification capabilities that are crucial for producing biologically active proteins. Yeast-based systems, including Saccharomyces cerevisiae and Pichia pastoris, are widely used for industrial-scale production due to their robustness and compatibility with complex protein structures. Fungi like Aspergillus niger and Trichoderma reesei are also gaining traction, particularly in enzyme production and industrial biotechnology applications.

The diagnostics segment will grow at a steady pace through 2032, as recombinant proteins are essential in diagnostic assays for detecting diseases and monitoring patient health. They are used to produce antigens, antibodies, and enzymes critical for diagnostic tests such as enzyme-linked immunosorbent assays (ELISA), lateral flow assays, and molecular diagnostics. The specificity, sensitivity, and reproducibility of recombinant proteins make them ideal for developing accurate and reliable diagnostic tools. As the global healthcare industry emphasizes early disease detection and personalized medicine, the demand for recombinant proteins in diagnostics is expected to grow.

Europe recombinant proteins industry will witness decent growth trends during 2024 and 2032, characterized by a strong biopharmaceutical sector, extensive research infrastructure, and supportive regulatory framework. Countries like Germany, Switzerland, and the United Kingdom are leading hubs for biotechnology and pharmaceutical research, driving demand for recombinant proteins in drug discovery and development. Moreover, stringent quality standards and favorable reimbursement policies for biopharmaceutical products contribute to market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for biopharmaceuticals and therapeutic proteins
  - 3.2.1.2 Advancements in protein engineering
  - 3.2.1.3 Growing prevalence of chronic and infectious diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High production costs
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Products
- 5.2.1 Cytokines & growth factors
  - 5.2.1.1 Interferons (IFNs)
  - 5.2.1.2 Interleukins (ILs)
  - 5.2.1.3 Other cytokines & growth factors
- 5.2.2 Antibodies
- 5.2.3 Immune checkpoint proteins
- 5.2.4 Virus antigens
- 5.2.5 Enzymes
  - 5.2.5.1 Kinases
  - 5.2.5.2 Metabolic enzymes
  - 5.2.5.3 Other enzymes
- 5.2.6 Recombinant regulatory proteins
- 5.2.7 Hormones
- 5.2.8 Other products
5.3 Production services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug discovery & development
- 6.2.1 Biologics
- 6.2.2 Vaccines
- 6.2.3 Cell & gene therapies
6.3 Research
6.4 Diagnostics
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Host-cell, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Mammalian systems
7.3 Insect cells
7.4 Yeast & fungi
7.5 Bacterial cells
7.6 Other host-cells

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical & biotechnology companies
8.3 Academic & research institutes
8.4 Contract research organizations (CRO's)
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa